We measured the serum levels of myoglobin, total creatine kinase (CK), and the CK
myocardial (CK-MB), muscle (CK-MM), and brain (CK-BB) isoenzymes in 37 subjects treated
with statins and 43 nonstatin-treated controls running the 2011 Boston Marathon. Venous
blood samples were obtained the day before (PRE) and within 1 hour (FINISH) and 24
hours after (POST) the race. The hematocrit and hemoglobin values were used to adjust
for changes in the plasma volume. The CK distribution was normalized using log transformation
before analysis. The exercise-related increase in CK 24 hours after exercise, adjusted
for changes in plasma volume, was greater in the statin users (PRE to POST 133 ± 15
to 1,104 ± 150 U/L) than in the controls (PRE to POST 125 ± 12 to 813 ± 137 U/L; p
= 0.03 for comparison). The increase in CK-MB 24 hours after exercise was also greater
in the statin users (PRE to POST 1.1 ± 3.9 to 8.9 ± 7.0 U/L) than in the controls
(PRE to POST 0.0 ± 0.0 to 4.2 ± 5.0 U/L; p <0.05 for comparison). However, the increases
in muscle myoglobin did not differ at any point between the 2 groups. Increases in
CK at both FINISH and POST race measurements were directly related to age in the statin
users (r2 = 0.13 and r2 = 0.14, respectively; p <0.05) but not in the controls (r2 = 0.02 and r2 = 0.00, respectively; p >0.42), suggesting that susceptibility to exercise-induced
muscle injury with statins increases with age. In conclusion, our results show that
statins increase exercise-related muscle injury.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- USA marathoning: 2009 overview.
- Major adverse cardiac events during endurance sports.Am J Cardiol. 2007; 99: 849-851
- Effect of marathon running on hematologic and biochemical laboratory parameters, including cardiac markers.Am J Clin Pathol. 2002; 118: 856-863
- Statin-associated myopathy.JAMA. 2003; 289: 1681-1690
- Lovastatin increases exercise-induced skeletal muscle injury.Metabolism. 1997; 46: 1206-1210
- Metabolic changes following eccentric exercise in trained and untrained men.J Appl Physiol. 1986; 61: 1864-1868
- Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.Clin Chem. 1972; 18: 499-502
- Physical activity and incidence of hypertension in college alumni.Am J Epidemiol. 1983; 117: 245-257
- Evaluation of hemoconcentration from hematocrit measurements.J Appl Physiol. 1972; 32: 712-713
- The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.Am J Cardiol. 1997; 80: 106-107
- Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients.Pharmacotherapy. 2008; 28: 553-561
- ACC/AHA/NHLBI clinical advisory on the use and safety of statins.J Am Coll Cardiol. 2002; 40: 567-572
- Influence of tart cherry juice on indices of recovery following marathon running.Scand J Med Sci Sports. 2010; 20: 843-852
- Creatine kinase elevations in marathon runners: relationship to training and competition.Yale J Biol Med. 1980; 53: 275-279
- Creatine kinase-MB isoenzyme adaptations in stressed human skeletal muscle of marathon runners.J Appl Physiol. 1985; 59: 149-153
- Elimination kinetics of myoglobin and creatine kinase in rhabdomyolysis: implications for follow-up.Crit Care Med. 2002; 30: 2212-2215
- Increases in creatine kinase after exercise in patients treated with HMG Co-A reductase inhibitors.JAMA. 1990; 264: 2992
- Effects of exercise and lovastatin on serum creatine kinase activity.Metabolism. 1991; 40: 1333-1336
- Lovastatin use and muscle damage in healthy volunteers undergoing eccentric muscle exercise.West J Med. 1991; 154: 198-200
- ATP and muscle enzyme efflux after physical exertion.Clin Chim Acta. 1975; 59: 241-245
- Creatine kinase monitoring in sport medicine.Br Med Bull. 2007; 81-82: 209-230
- Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications.Muscle Nerve. 2011; 43: 76-81
- Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins.Arterioscler Thromb Vasc Biol. 2005; 25: 2560-2566
- Investigation of gene expression in C(2)C(12) myotubes following simvastatin application and mechanical strain.J Atheroscler Thromb. 2009; 16: 21-29
- Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system.J Pharmacol Exp Ther. 2007; 321: 626-634
- Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity.Toxicol Sci. 2005; 88: 551-561
- Cardiac injury markers in non-elite marathon runners.Int J Sports Med. 2009; 30: 75-79
- The metabolic effects of exercise-induced muscle damage.Exerc Sport Sci Rev. 1991; 19: 99-125
- HMG-CoA reductase inhibitors and the kidney.Kidney Int. 2007; 71: 1215-1222
- Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems.Br J Clin Pharmacol. 2004; 57: 525-528
Article Info
Publication History
Published online: October 31, 2011
Accepted:
August 30,
2011
Received in revised form:
August 30,
2011
Received:
July 26,
2011
Footnotes
This study was funded by a research grant from Hartford Hospital (Hartford, Connecticut).
Dr. Thompson is a consultant for AstraZenica International, Wilmington, Delaware, Merck & Co., Inc., Whitehouse Station, New Jersey, the Schering-Plough Corporation, Kenilworth, New Jersey, Takeda Pharmaceutical Company, Limited, Deerfield, Illinois, Roche, Inc., Indianapolis, Indiana, and Genomas, Inc., Hartford, Connecticut and is a member of the speaker's bureau for Merck & Co., Inc., Whitehouse Station, New Jersey, Pfizer, Inc., Groton, Connecticut, Abbott Laboratories, Abbott Park, Illinois, AstraZenica International, Wilmington, Delaware, and the Schering-Plough Corporation, Kenilworth, New Jersey.
Identification
Copyright
© 2012 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
